Work

Fever for days: A challenging case of dalbavancin-induced fever

Year: 2024

Type: article

Abstract: Dalbavancin is a novel long acting lipoglycopeptide antibiotic with a favorable safety profile approved for treating Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by Gram-positive organisms. Given its long half-life, a two-dose regimen can provide effective systemic therapy for up to six weeks, making it an appealing option to avoid prolonged intravenous antibiotic therapy. Herein, we report a case of a 27-year-old male who developed dalbavancin-induced fever while treating Methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia. Despite being inconsistently reported, our case highlights fever as a possible side effect of dalbavancin therapy, and the challenging management of this adverse event given its prolonged half-life.

Source: IDCases

DOI: 10.1016/j.idcr.2024.e02138

Authors: Mohamed A. Almahal, Claire Wan, Benjamin Albrecht, Sarah Green, Ahmed Babiker

Institutions: Emory University, Rush University Medical Center

Language: English

Topic: Antimicrobial Resistance in Staphylococcus

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,150